Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Matrices
Reexamination Certificate
1997-09-22
2003-02-04
Webman, Edward J. (Department: 1617)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Matrices
C424S468000, C424S457000, C514S970000
Reexamination Certificate
active
06514533
ABSTRACT:
BACKGROUND OF THE INVENTION
Many illnesses or conditions require administration of a constant or sustained level of a medicament or biologically active agent to provide the most effective prophylactic or therapeutic. This may be accomplished through a multiple dosing regimen or by employing a system that releases the medicament in a sustained fashion.
Attempts to sustain medication levels include the use of biodegradable materials, such as polymeric matrices, containing the medicament. The use of these matrices, for example, in the form of microparticles or microcarriers, provides an improvement in the sustained release of medicaments by utilizing the inherent biodegradability of the polymer to control the release of the medicament and provide a more consistent, sustained level of medication and improved patient compliance.
However, these sustained release devices often exhibited high initial bursts of agent release and minimal agent release thereafter. Further, due to the high solution concentration of agent within and localized around these sustained release devices, the agent molecules have tended to aggregate thereby increasing immunogenicity in vivo and interfering with the desired release profile for the agent.
Therefore, a need exists for a means for sustaining the release of a biologically active agent in vivo without significant aggregate formation and thus with a reduced immune response to the agent over the release period of the agent.
SUMMARY OF THE INVENTION
This invention relates to a device for the sustained release in vivo of a water soluble, biologically active agent wherein said agent is susceptible to aggregation, comprising a drug delivery device and aggregation-stabilized, biologically active agent wherein the aggregation-stabilized agent is disposed within the drug delivery device.
There are many advantages to this sustained release device for a biologically active agent. These advantages include longer, more consistent in vivo blood levels of the agent, lower initial bursts of the agent, and increased therapeutic benefits by eliminating fluctuations in serum agent levels. The advantages also include better retention of biological activity of the agent and reduced immunogenicity when in vivo. The advantages further include more complete release of an agent from a sustained release device.
REFERENCES:
patent: 3887699 (1975-06-01), Yolles
patent: 3891570 (1975-06-01), Fukushima et al.
patent: 4235236 (1980-11-01), Theeuwes
patent: 4252791 (1981-02-01), Grossberg et al.
patent: 4391797 (1983-07-01), Folkman et al.
patent: 4530840 (1985-07-01), Tice et al.
patent: 4542025 (1985-09-01), Tice et al.
patent: 4637905 (1987-01-01), Gardner
patent: 4675189 (1987-06-01), Kent et al.
patent: 4835139 (1989-05-01), Tice et al.
patent: 4853218 (1989-08-01), Yim et al.
patent: 4897268 (1990-01-01), Tice et al.
patent: 4962091 (1990-10-01), Eppstein et al.
patent: 5019400 (1991-05-01), Gombotz et al.
patent: 5126147 (1992-06-01), Silvestri et al.
patent: 5192741 (1993-03-01), Orsolini et al.
patent: 5441734 (1995-08-01), Reichert et al.
patent: 5697922 (1997-12-01), Thombre
patent: 6087324 (2000-07-01), Igari et al.
patent: 6376461 (2002-04-01), Igari et al.
patent: 0266119 (1987-10-01), None
patent: WO 90/13285 (1990-11-01), None
patent: WO 90/13780 (1990-11-01), None
patent: WO 92/11844 (1992-07-01), None
patent: WO 91/12882 (1992-09-01), None
patent: WO 93/17668 (1993-09-01), None
patent: WO 93/25221 (1993-12-01), None
patent: WO 94/12158 (1994-06-01), None
patent: WO 95/11010 (1995-04-01), None
patent: WO 95/29664 (1995-11-01), None
patent: WO 96/07399 (1996-03-01), None
Santo, Toyomi et al., “Porous Biodegradable Microspheres for Controlled Drug Delivery. I. Assessment of Processing Conditions and Solvent Removal Techniques,”Pharmaceutical Research, 5(1):21-29 (1988).
Langer, R., “New Methods of Drug Delivery,”Science, 249:1527-1533 (Sep. 28, 1990).
Liu, W.R. et al., “Moisture-Induced Aggregation of Lyophilized Proteins in the Solid State,”Biotechnology and Bioengineering, 37:177-184 (1991).
Lu, W. and Park, T.G., “Protein Release from Poly(lactic-co-glycolic acid) Microspheres: Protein Stability Problems,”PDA Journal of Pharmaceutical Science&Technology, 49(1):13-19 (Jan.-Feb. 1995).
Cohen, S. et al., “Controlled Delivery Systems for Proteins Based on Poly(Lactic/Glycolic Acid) Microspheres,”Pharmaceutical Research, 8(6):713-720 (1991).
Hora, M.S. et al., “Release of Human Serum Albumin from Poly(latide-co-glycolide) Microspheres,”Pharmaceutical Research, 7(11):1190-1194 (1990).
Hageman, M.J. et al., “Preformulation Studies Oriented Toward Sustained Delivery of Recombinant Somatotropins,”J. Agric. Food Chem., 40:348-355 (1992).
Cleland, J.L. et al., “Characterization of Recombinant Human Growth Hormone-PLGA Formulations in Animals,”Proceed, Intern. Symp. Control. Rel. Bioact. Mater., 22:143-144 (1995).
Park, T.G. et al., “Importance of In Vitro Experimental Conditions on Protein Release Kinetics, Stability and Polymer Degradation in Protein Encasulated Poly(D,L-Lactic Acid-Co-Glycolic Acid) Microspheres,”Journal of Controlled Release, 33:211-222 (1995).
Auer Henry E.
Bernstein Howard
Burke Paul A.
Johnson OluFunmi Lily
Khan M. Amin
Alkermas Controlled Therapeutics, Inc.
Hamilton Brook Smith & Reynolds P.C.
Webman Edward J.
LandOfFree
Device for the sustained release of aggregation-stabilized,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Device for the sustained release of aggregation-stabilized,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Device for the sustained release of aggregation-stabilized,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3116326